Loading…
MacroGenics, Inc. is projected to rise to $5.53 by 2027, a +50% move from its current price of $3.69. MGNX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.55 | $3.69 | $3.85 | +0.09% |
| Aug 4 | $3.49 | $3.70 | $3.91 | +0.18% |
| Aug 5 | $3.45 | $3.70 | $3.97 | +0.28% |
| Aug 6 | $3.42 | $3.70 | $4.01 | +0.37% |
| Aug 7 | $3.39 | $3.71 | $4.06 | +0.46% |
| Aug 8 | $3.36 | $3.71 | $4.10 | +0.55% |
| Aug 9 | $3.34 | $3.71 | $4.13 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.34 | $3.71 | $4.13 | +0.65% |
| Week 2 | $3.21 | $3.74 | $4.35 | +1.29% |
| Week 3 | $3.13 | $3.76 | $4.52 | +1.95% |
| Week 4 | $3.06 | $3.79 | $4.69 | +2.61% |
| Week 5 | $3.00 | $3.81 | $4.84 | +3.27% |
| Week 6 | $2.95 | $3.84 | $4.98 | +3.93% |
| Week 7 | $2.91 | $3.86 | $5.12 | +4.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc. (MGNX) is currently priced at $3.67 per share. The market capitalization stands at $233.28M, and the stock ranks 3693. The current price and its market position place the company among smaller-cap biopharma stocks with ongoing late-stage and preclinical programs.
The forecasted price path suggests an initial neutral stance in 2026, followed by a sustained bullish trajectory in later years, with average prices rising from $3.67 in 2026 to multi-digit levels by 2050. In 2026 the min, avg, and max are $1.61, $3.67, and $5.87 respectively, with an implied neutral sentiment; from 2027 onward, the outlook turns bullish, with 2030, 2040, and 2050 averages projected at $6.57, $17.60, and $32.32 and corresponding ROIs of 78.9, 379.5, and 780.6. The forecast also shows a 30-day range of $2.78 to $4.84 and a technical backdrop indicating a bullish longer-term potential alongside a near-term volatility.
A major floor 26.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.5% away) — a key level to hold.
The nearest ceiling, 31.7% above — a clean break opens room to run.
A major ceiling 42.6% above — clearing it would confirm fresh momentum.
Key MGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.80 | Sell | $3.79 | Sell |
| MA 10 | $3.99 | Sell | $3.94 | Sell |
| MA 20 | $4.22 | Sell | $4.10 | Sell |
| MA 50 | $4.27 | Sell | $4.08 | Sell |
| MA 100 | $3.77 | Sell | $3.70 | Sell |
| MA 200 | $2.72 | Buy | $3.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.16 | Neutral |
| Stoch RSI (14) | 16.42 | Buy |
| CCI (20) | -119.88 | Sell |
| Williams %R (14) | -97.70 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -14.58 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 2.30 | Buy |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.52 | Sell |
| Ultimate (7,14,28) | 32.41 | Neutral |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 3.64 | Buy |
| ADX (14) | 14.96 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day range is $2.78 to $4.84. The RSI14 sits at 40, with the 50-day simple moving average at $4.30 and the 200-day simple moving average at $2.70. Immediate support is at $3.67 and resistance at $4.86, framing a tight near-term band around the current price.
The technical picture reflects a bullish tilt in the near term amid a modestly cooled RSI and a price sitting above the long-term moving average while still near the lower half of the 30-day range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $3.69 | $5.81 | 0% | Neutral | |
| $4.22 | $5.53 | $7.77 | +50% | Bullish | |
| $4.19 | $5.74 | $8.49 | +56% | Bullish | |
| $4.32 | $6.13 | $9.44 | +66% | Bullish | |
| $4.51 | $6.62 | $10.54 | +80% | Bullish | |
| $4.29 | $6.49 | $10.63 | +76% | Bullish | |
| $5.54 | $8.62 | $14.49 | +134% | Bullish | |
| $6.69 | $10.70 | $18.39 | +190% | Bullish | |
| $6.61 | $10.84 | $19.02 | +194% | Bullish | |
| $6.96 | $11.70 | $20.94 | +217% | Bullish | |
| $9.29 | $17.57 | $34.07 | +376% | Bullish | |
| $14.62 | $32.49 | $70.63 | +780% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.61 | $3.69 | $4.78 | +0.00% |
| September 2026 | $3.37 | $4.04 | $5.02 | +9.46% |
| October 2026 | $3.31 | $4.01 | $5.06 | -0.65% |
| November 2026 | $3.45 | $4.22 | $5.39 | +5.09% |
| December 2026 | $3.65 | $4.50 | $5.81 | +6.68% |
Click any year to see its month-by-month MGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MGNX could reach as high as $5.81, with a base case around $3.69 and support toward $1.61 — roughly 0% from $3.69. A consolidation phase looks the most probable path here.
Expect MGNX to range from $4.22 to $7.77 through 2027. The $5.53 average target implies a +50% move from current prices. That is up +50% on the projected 2026 average. Momentum favours further upside here.
The MGNX price prediction for 2028 points to an average of $5.74 (low $4.19, high $8.49) — a potential gain of +56% on today's $3.69. Buyers look set to stay in control over this stretch.
In 2029, MGNX is projected to trade between $4.32 and $9.44, averaging $6.13 — a potential gain of +66% from today's $3.69. That is up +7% on the projected 2028 average. Momentum favours further upside here.
MacroGenics, Inc.'s 2030 outlook centres on $6.62, within a $4.51 to $10.54 range. That is up +8% on the projected 2029 average. That marks a +80% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MGNX could reach as high as $10.63, with a base case around $6.49 and support toward $4.29 — roughly +76% from $3.69. Momentum favours further upside here.
Expect MGNX to range from $5.54 to $14.49 through 2032. The $8.62 average target implies a +134% move from current prices. That is up +33% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The MGNX price prediction for 2033 points to an average of $10.70 (low $6.69, high $18.39) — a potential gain of +190% on today's $3.69. Momentum favours further upside here.
In 2034, MGNX is projected to trade between $6.61 and $19.02, averaging $10.84 — a potential gain of +194% from today's $3.69. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
MacroGenics, Inc.'s 2035 outlook centres on $11.70, within a $6.96 to $20.94 range. That is up +8% on the projected 2034 average. That marks a +217% change versus current levels. Momentum favours further upside here.
By 2040, MGNX could reach as high as $34.07, with a base case around $17.57 and support toward $9.29 — roughly +376% from $3.69. Buyers look set to stay in control over this stretch.
Expect MGNX to range from $14.62 to $70.63 through 2050. The $32.49 average target implies a +780% move from current prices. That is up +85% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MGNX today (≈ 271.00271 MGNX) could be worth
$8,804.22
+$7,804.22 (+780%) by 2050 · US Dollar
Based on the average projected MGNX price of $32.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGNXwould be worth at today's price.
$1,000 invested in MGNX on Jul 31, 2025 (≈ 641.025665 MGNX) would be worth
$2,365.38
+$1,365.38 (+136.5%) today · 2.37× · US Dollar
Based on a MGNX entry price of $1.56 vs. today's $3.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.7 | $997.3 | -0.3% |
| 1 month ago | $4.62 | $798.7 | -20.1% |
| 3 months ago | $3.13 | $1,178.91 | +17.9% |
| 6 months ago | $1.75 | $2,108.57 | +110.9% |
| 1 year ago | $1.56 | $2,365.38 | +136.5% |
| All time (5.0y) ago | $24.9 | $148.19 | -85.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGNX forecast.
Our base-case forecast reaches $7.40 around 2032.
Implied market cap at $7.40: $470.37M
Looking across the multi-year forecast, the sentiment shifts from neutral in 2026 to bullish from 2027 onward. The 2026 forecast shows a min of $1.61, an average of $3.67, and a max of $5.87, with an ROI of 0 and a neutral stance. By 2030 the average is projected at $6.57 with an ROI of 78.9 and a bullish outlook, while the 2040 forecast climbs to an average of $17.60 with an ROI of 379.5 and a bullish stance, and by 2050 the average is $32.32 with an ROI of 780.6 and a bullish stance.
Year-by-year milestones include 2032 avg $8.61 (ROI 134.7), 2033 avg $10.72 (ROI 192.1), 2034 avg $10.87 (ROI 196.3), and 2035 avg $11.65 (ROI 217.5). These figures imply meaningful upside over the longer horizon, but they are estimates and not guarantees. The forecast envisions substantial upside potential from 2027 onward, with rising averages and persistent bullish sentiment through 2050, alongside inherent uncertainty and the possibility of deviations from these projections.
Tap a question to reveal the answer.
In 2030, the average forecast price is $6.57, with a low of $4.42 and a high of $10.58. ROI is 78.9 and sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward, with 2030, 2040, and 2050 averages of $6.57, $17.60, and $32.32 and ROIs of 78.9, 379.5, and 780.6, respectively. The 2026 value is $3.67 with neutral sentiment. These are estimates, not guarantees.
Yes. The forecast lists a max of $21.18 in 2035, with earlier years showing maxes of $18.70 in 2033 and $19.38 in 2034, suggesting the target of $20 could be surpassed by 2035.
Current price is $3.67 and market cap is $233.28M.
The 30-day range is $2.78 to $4.84.
MacroGenics, Inc. Community Discussion
0Share your MacroGenics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.